Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer.
Saved in:
| Title: | Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer. |
|---|---|
| Authors: | Palomero J; Tumor Immunology and Immunotherapy, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Panisello C; Tumor Immunology and Immunotherapy, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Lozano-Rabella M; Tumor Immunology and Immunotherapy, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Tirtakasuma R; Tumor Immunology and Immunotherapy, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Díaz-Gómez J; Tumor Immunology and Immunotherapy, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Grases D; Tumor Immunology and Immunotherapy, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Pasamar H; Tumor Immunology and Immunotherapy, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Arregui L; HUB-ICO-IDIBELL Biobank, Bellvitge Institute for Biomedical Research, L'Hospitalet de Llobregat, Spain., Dorca Duch E; Pathology, Bellvitge University Hospital, IDIBELL, L'Hospitalet de Llobregat, Spain., Guerra Fernández E; Pathology, Bellvitge University Hospital, IDIBELL, L'Hospitalet de Llobregat, Spain., Vivancos A; Cancer Genomics, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., de Andrea CE; Pathology, Clinica Universidad de Navarra, Pamplona, Spain.; Centro de Investigación Biomedica en Red de Cáncer (CIBERONC), Madrid, Spain., Melero I; Centro de Investigación Biomedica en Red de Cáncer (CIBERONC), Madrid, Spain.; Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Pamplona, Spain.; Navarra Institute for Health Research IDISNA, Pamplona, Spain., Ponce J; Department of Gynaecology, Bellvitge University Hospital, L'Hospitalet de Llobregat, Spain., Vidal A; Pathology, Bellvitge University Hospital, IDIBELL, L'Hospitalet de Llobregat, Spain.; Centro de Investigación Biomedica en Red de Cáncer (CIBERONC), Madrid, Spain., Piulats JM; Medical Oncology, Catalan Institute of Oncology (ICO), IDIBELL-OncoBell, L'Hospitalet de Llobregat, Spain., Matias-Guiu X; Pathology, Bellvitge University Hospital, IDIBELL, L'Hospitalet de Llobregat, Spain.; Centro de Investigación Biomedica en Red de Cáncer (CIBERONC), Madrid, Spain.; Pathology, Arnau de Vilanova University Hospital, University of LLeida, IRBLLEIDA, Lleida, Spain., Gros A; Tumor Immunology and Immunotherapy, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain agros@vhio.net. |
| Source: | Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Dec; Vol. 10 (12). |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
